Last reviewed · How we verify
Phentolamine Mesylate Ophthalmic Solution 1%
At a glance
| Generic name | Phentolamine Mesylate Ophthalmic Solution 1% |
|---|---|
| Also known as | Nyxol®, Nyxol |
| Sponsor | Ocuphire Pharma, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances (PHASE3)
- Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia (PHASE2)
- Adjusted Study Protocol: Within-Subject Paired-Eye Design Comparing Pilocarpine 0.1%, Phentolamine 0.75%, and Combination Therapy for Cyclopentolate Reversal in Children (NA)
- Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances (PHASE2)
- Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma (PHASE2)
- Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis (PHASE3)
- Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects (PHASE3)
- Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: